tesamorelin acetate: Frequently asked questions

Peptides below 95% purity contain significant impurities. Truncated sequences, aggregated dimers, or synthesis byproducts that interfere with GHRH receptor binding. Research-grade tesamorelin acetate should consistently test ≥98% purity via HPLC. If your supplier's batch tests below 95%, request a replacement or source from a verified 503B-registered facility. Impure peptides not only reduce efficacy but also increase the risk of immune reactions due to contaminated sequences the body recognizes as foreign.

Proceed with standard reconstitution. The product is almost certainly tesamorelin acetate regardless of labeling. Free-base tesamorelin (without a stabilizing counterion) is not viable for commercial distribution because it degrades within hours at room temperature. Contact your supplier to confirm the molecular weight listed on the CoA matches 5255 Da or 5136 Da (both acceptable). If the supplier cannot provide a CoA with molecular weight and purity verification, do not use the product. Absence of documentation indicates inadequate quality control.

Discard the vial. Freezing reconstituted peptides causes ice crystal formation that ruptures peptide structures and denatures the molecule irreversibly. Once thawed, the solution may appear clear, but HPLC analysis would show fragmented peptides and aggregated dimers that no longer bind GHRH receptors effectively. Lyophilized (unreconstituted) tesamorelin acetate tolerates freezing at −20°C indefinitely, but once dissolved, it must remain refrigerated at 2–8°C without temperature excursions.

Check timing of GH measurement and reconstitution accuracy. Tesamorelin acetate produces peak GH secretion 60–90 minutes post-injection, with GH concentrations returning toward baseline by 4–6 hours. Measuring GH levels at trough (pre-injection or >6 hours post-dose) will not capture the GH pulse. Additionally, incorrect reconstitution—using the wrong diluent volume or failing to fully dissolve the peptide—can result in underdosing. Tesamorelin acetate is typically reconstituted with 2.1–2.2 mL bacteriostatic water for a final concentration of approximately 1mg/mL; verify that the lyophilized cake dissolves completely before drawing the dose. If reconstitution and timing are correct but GH response is still absent, consider pituitary function—subjects with somatotroph insufficiency or prior pituitary damage may have blunted responses to GHRH stimulation.

Rotate injection sites and verify proper subcutaneous technique. Injection-site reactions (erythema, induration, pruritus) occur in approximately 30% of tesamorelin acetate administrations, typically resolving within 3–7 days. Persistent reactions beyond one week suggest repeated trauma to the same site or improper injection depth. Subcutaneous injections should target the fatty layer between skin and muscle—using too short a needle or injecting at an angle can deposit peptide into dermal tissue, increasing local inflammation. Recommended rotation sites include the abdomen (avoiding the 2-inch radius around the navel), anterior thigh, and outer upper arm. Allow at least 1 inch between consecutive injection points and avoid returning to the same site within 7 days. If reactions persist despite proper rotation, consider benzyl alcohol sensitivity—bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which can cause localized hypersensitivity in some individuals. Switching to sterile water for injection (though this reduces shelf life to 24 hours post-reconstitution) may resolve the issue.

Implement glucose monitoring and assess pre-existing insulin resistance. Tesamorelin acetate increases hepatic glucose output and reduces peripheral insulin sensitivity through GH's counter-regulatory effects. Mean fasting glucose increases of 3–5 mg/dL are expected, but increases exceeding 10 mg/dL suggest baseline glucose dysregulation or higher-than-expected GH receptor sensitivity. Fasting glucose should be measured at baseline, week 4, week 12, and then every 8–12 weeks during continued use. If fasting glucose rises above 100 mg/dL or HbA1c increases by more than 0.3%, consider dose reduction or discontinuation—chronic hyperglycemia outweighs the metabolic benefits of VAT reduction. Subjects with pre-existing prediabetes (fasting glucose 100–125 mg/dL) or metabolic syndrome are at highest risk for glucose intolerance during tesamorelin acetate administration.

Discard the vial and reconstitute a fresh sample. Tesamorelin acetate degrades rapidly above 8°C once reconstituted with bacteriostatic water—peptide bonds are susceptible to hydrolysis and oxidation at ambient temperatures. While lyophilized (freeze-dried) tesamorelin acetate powder is stable at −20°C for 24–36 months, the reconstituted solution must be refrigerated at 2–8°C and used within 14 days per stability data. A temperature excursion to 20–25°C for 48 hours causes measurable potency loss, and you cannot verify peptide integrity visually—degraded tesamorelin acetate looks identical to intact peptide. The small cost of discarding a compromised vial is negligible compared to unreliable experimental results from degraded material.